AIMS: The Ethnic Minority Meta-Analysis (EMMA) aims to assess racial/ethnic disparities in HIV infection among people who inject drugs (PWID) across various countries. This is the first report of the data. METHODS: Standard systematic review/meta-analysis methods were utilized, including searching for, screening and coding published and unpublished reports and meta-analytical statistics. We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for reporting methods. Disparities were measured with the odds ratio (OR) for HIV prevalence among ethnic minority PWID compared to ethnic majority PWID; an OR >1.0 indicated higher prevalence among ethnic minorities. RESULTS: Racial/ethnic disparities in HIV prevalence among PWID were examined in 131 prevalence reports, with 214 racial/ethnic minority to majority comparisons, comprising 106 715 PWID. Overall, the pooled OR indicates an increased likelihood of higher HIV prevalence among racial/ethnic minority compared to racial/ethnic majority PWID [OR = 2.09, 95% confidence interval (CI): 1.92-2.28]. Among 214 comparisons, 106 produced a statistically significant higher OR for minorities; in 102 comparisons the OR was not significantly different from 1.0; six comparisons produced a statistically significant higher OR for majority group members. Disparities were particularly large in the United States, pooled OR = 2.22 (95% CI: 2.03-2.44). There was substantial variation in ORs-I(2) = 75.3%: interquartile range = 1.38-3.56-and an approximate Gaussian distribution of the log ORs. CONCLUSIONS: Among people who inject drugs, ethnic minorities are approximately twice as likely to be HIV seropositive than ethnic majorities. The great heterogeneity and Gaussian distribution suggest multiple causal factors and a need to tailor interventions to local conditions.
AIMS: The Ethnic Minority Meta-Analysis (EMMA) aims to assess racial/ethnic disparities in HIV infection among people who inject drugs (PWID) across various countries. This is the first report of the data. METHODS: Standard systematic review/meta-analysis methods were utilized, including searching for, screening and coding published and unpublished reports and meta-analytical statistics. We followed the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) statement and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines for reporting methods. Disparities were measured with the odds ratio (OR) for HIV prevalence among ethnic minority PWID compared to ethnic majority PWID; an OR >1.0 indicated higher prevalence among ethnic minorities. RESULTS: Racial/ethnic disparities in HIV prevalence among PWID were examined in 131 prevalence reports, with 214 racial/ethnic minority to majority comparisons, comprising 106 715 PWID. Overall, the pooled OR indicates an increased likelihood of higher HIV prevalence among racial/ethnic minority compared to racial/ethnic majority PWID [OR = 2.09, 95% confidence interval (CI): 1.92-2.28]. Among 214 comparisons, 106 produced a statistically significant higher OR for minorities; in 102 comparisons the OR was not significantly different from 1.0; six comparisons produced a statistically significant higher OR for majority group members. Disparities were particularly large in the United States, pooled OR = 2.22 (95% CI: 2.03-2.44). There was substantial variation in ORs-I(2) = 75.3%: interquartile range = 1.38-3.56-and an approximate Gaussian distribution of the log ORs. CONCLUSIONS: Among people who inject drugs, ethnic minorities are approximately twice as likely to be HIV seropositive than ethnic majorities. The great heterogeneity and Gaussian distribution suggest multiple causal factors and a need to tailor interventions to local conditions.
Authors: Richard H Needle; Robert T Trotter; Merrill Singer; Christopher Bates; J Bryan Page; David Metzger; Louis H Marcelin Journal: Am J Public Health Date: 2003-06 Impact factor: 9.308
Authors: D F Stroup; J A Berlin; S C Morton; I Olkin; G D Williamson; D Rennie; D Moher; B J Becker; T A Sipe; S B Thacker Journal: JAMA Date: 2000-04-19 Impact factor: 56.272
Authors: Carl Latkin; Aylur K Srikrishnan; Cui Yang; Sethulakshmi Johnson; Sunil S Solomon; Suresh Kumar; David D Celentano; Suniti Solomon Journal: Drug Alcohol Depend Date: 2010-05-13 Impact factor: 4.492
Authors: Nina T Harawa; Sander Greenland; Trista A Bingham; Denise F Johnson; Susan D Cochran; William E Cunningham; David D Celentano; Beryl A Koblin; Marlene LaLota; Duncan A MacKellar; William McFarland; Douglas Shehan; Sue Stoyanoff; Hanne Thiede; Lucia Torian; Lucia A Valleroy Journal: J Acquir Immune Defic Syndr Date: 2004-04-15 Impact factor: 3.731
Authors: Rebecca K Stern; Holly Hagan; Corina Lelutiu-Weinberger; Don Des Jarlais; Roberta Scheinmann; Shiela Strauss; Enrique R Pouget; Peter Flom Journal: BMC Med Res Methodol Date: 2008-09-14 Impact factor: 4.615
Authors: Ali Mirzazadeh; Jennifer L Evans; Judith A Hahn; Jennifer Jain; Alya Briceno; Stephen Shiboski; Paula J Lum; Christopher Bentsen; Geoff Davis; Kathy Shriver; Melanie Dimapasoc; Mars Stone; Michael P Busch; Kimberly Page Journal: AIDS Behav Date: 2018-04
Authors: Don C Des Jarlais; Kamyar Arasteh; Courtney McKnight; Jonathan Feelemyer; Susan Tross; David Perlman; Samuel Friedman; Aimee Campbell Journal: Am J Public Health Date: 2017-05-18 Impact factor: 9.308
Authors: Alan Neaigus; Kathleen H Reilly; Samuel M Jenness; Holly Hagan; Travis Wendel; Camila Gelpi-Acosta; David M Marshall Journal: J Acquir Immune Defic Syndr Date: 2017-07-01 Impact factor: 3.731
Authors: Courtney McKnight; Martha Shumway; Carmen L Masson; Enrique R Pouget; Ashly E Jordan; Don C Des Jarlais; James L Sorensen; David C Perlman Journal: J Ethn Subst Abuse Date: 2017-03-17 Impact factor: 1.507
Authors: Samuel R Friedman; Barbara Tempalski; Joanne E Brady; Brooke S West; Enrique R Pouget; Leslie D Williams; Don C Des Jarlais; Hannah L F Cooper Journal: Int J Drug Policy Date: 2016-03-11